
Keratolytic drug for MGD
Meibomian gland dysfunction (MGD) is characterised by alterations in glandular secretion and terminal duct obstruction, secondary to hyperkeratinisation of the ductal epithelium1. The oils secreted from the glands contain a mixture of lipid secretions and keratinised epithelial debris. Keratin level












-1.png&w=1920&q=75)
